How Coultreon pulled off a $125M Series A

In this session, Pieter Peeters and Guy Peeters take us behind the scenes of Coultreon Biopharma’s record-breaking Belgian biotech funding round. The company raised $125 million from an international investor syndicate to advance its immunology pipeline, including a potential first-in-class, once-daily oral therapy for autoimmune diseases.

• How do you build enough scientific, clinical and strategic confidence to convince international investors?
• How do you keep the company going before the money arrives?
• What happens in the months when the ambition is huge, but the runway is not?
• And when do you realise that your innovation has touched something investors truly believe in?

For patients, Coultreon’s ambition also carries a very human promise: moving from burdensome injections or infusions towards oral treatments that could make chronic therapy more convenient.

You will gain a rare inside view of what it takes to raise a record-breaking biotech Series A: the science, the pressure, the investor trust and the raw founder reality behind the funding headline.